Seoul, Seoul-t'ukpyolsi, South Korea Daehwa Pharmaceutical is the famous Corporate Investor, which was founded in 1984. The fund was located in Asia if to be more exact in South Korea. The main office of represented Corporate Investor is situated in the Seoul.
The fund is constantly included in less than 2 deals per year. The top activity for fund was in 2019. Deals in the range of more than 100 millions dollars are the general things for fund.
For fund there is no match between the country of its foundation and the country of its the most frequent investments - China. Among the most successful fund investment fields, there are Biopharma, Biotechnology. Among the various public portfolio startups of the fund, we may underline Haihe Biopharma Besides, a startup needs to be aged 6-10 years to get the investment from the fund.
The standard case for the fund is to invest in rounds with 9 partakers. The meaningful sponsors for the fund in investment in the same round are Yingke Capital, Huagai Capital, Hillhouse Capital Group.
| Fund Name | Location |
| Aeterna Capital | Florida, Miami Beach, United States |
| Alsace Business Angels | Alsace, France, Illkirch-graffenstaden |
| Applied Genetics Technologies Corporation | Alachua, Florida, United States |
| CION Investments | Braintree, Massachusetts, United States |
| CQDM | Canada, Montreal, Quebec |
| Sistema Asia Fund | Central Region, Singapore, Singapore |
| TEN13 | Australia, Brisbane, Queensland |
| The Hit Forge | California, San Francisco, United States |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Haihe Biopharma | $146M | 11 Feb 2019 | Shanghai |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Haihe Biopharma | $146M | 11 Feb 2019 | Shanghai |
